News | February 03, 2023
Dabur India consolidated Q3FY23 PAT lower at Rs. 475.94 Cr
The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022
The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Cell sorting technology supports researchers advancing new therapies
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Subscribe To Our Newsletter & Stay Updated
